Feature | May 18, 2011 | Adhir Shroff, M.D., MPH

Review of the RIVAL Trial

Transradial has lower vascular complication, bleeding rates than transfemoral access

Figure 1: Access site and bleeding outcomes from the RIVAL trial.


The results of the highly anticipated RIVAL (RadIal Vs. femorAL access for coronary intervention)[1,2] trial were presented April 4 at the American College of Cardiology (ACC) 2011 Scientific Session in New Orleans. The basis of the trial was to investigate the efficacy and safety of the transradial approach as compared to the femoral approach in patients being treated with an invasive strategy for an acute coronary syndroThe results of the highly anticipated RIVAL (RadIal Vs. femorAL access for coronary intervention)[1,2] trial were presented April 4 at the American College of Cardiology’s 2011 Scientific Session in New Orleans.  The basis of the trial was to investigate the efficacy and safety of the transradial approach as compared to the femoral approach in patients being treated with an invasive strategy for an acute coronary syndrome.

Presenting the results was Sanjit Jolly, M.D., M.Sc., assistant professor of medicine at McMaster University in Hamilton, Ontario, Canada, who explained the radial approach affords a decrease in bleeding and vascular complications.  Several reports have linked bleeding events following coronary intervention to an increased risk of death. Prior to this study, there have been only retrospective studies or pooled analyses that have suggested the radial approach as superior to femoral artery access.

Patients with an acute coronary syndrome were randomized to either the transradial or transfemoral approach. Anticoagulation strategy was left to the discretion of the operator. More than 7,000 patients were included in this multicenter study. The primary endpoints included the occurrence of death, myocardial infarction, stroke or non-coronary artery bypass graft related major bleeding within 30 days.

The key findings of the RIVAL study included:
• Primary outcome was equivalent between radial and femoral groups (3.7 vs. 4 percent, p=0.50)
• Less vascular access site complications with radial compared to femoral access (p<0.0001) (Figure 1)
• Access site crossover was higher in the radial group (7.6 vs. 2 percent, p<0.0001)
• All access site major bleeds in the radial group occurred in those patients who crossed over to the femoral group
• High-volume radial centers had a benefit for the primary outcome compared with femoral access group (p=0.021)
• Patients with ST-elevated myocardial infarction (STEMI) benefited from transradial access for the composite endpoint of death, heart attack and stroke (p=0.011) and death alone (p=0.001) (Figure 2)

In summary, the authors concluded there was no difference in rates of composite death, myocardial infarction, stroke or major bleeding between access strategies, but radial access decreased major vascular complications. Expertise with the transradial technique and procedure volume may be linked to the effectiveness of this approach.

References:
1.    Jolly SS, Niemelä K, Xavier D, et al. “Design and rationale of the RadIal Vs. femorAL access for coronary intervention (RIVAL) trial: A randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes.” American Heart Journal 2011, 161:254-60.

2.    Jolly SS, Yusuf S, Cairns J, Kari Niemelä DX, Petr Widimsky, Andrzej Budaj, Matti Niemelä, Vicent Valentin, Basil S Lewis,, Alvaro Avezum PGS, Sunil V Rao, Peggy Gao, Rizwan Afzal, Campbell D Joyner, Susan Chrolavicius, Shamir R Mehta, for the group. “Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial.” Lancet 2011. DOI:https://doi.org/10.1016/S0140-6736(11)60404-2

3.    Jolly SS. “A randomized comparison of RadIal Vs. femorAL access for coronary intervention in ACS (RIVAL).” American College of Cardiology Scientific Sessions, New Orleans, 2011.

Related Content

News | Cardiovascular Clinical Studies

June 24, 2021 — Data captured in American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR) ...

Home June 24, 2021
Home
News | Cardiovascular Clinical Studies

January 27, 2021 — A New York Institute of Technology research team has secured a five-year $1.8 million grant from the ...

Home January 27, 2021
Home
News | Cardiovascular Clinical Studies

July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to ...

Home July 22, 2020
Home
News | Cardiovascular Clinical Studies

July 1, 2020 — Carag AG announced receiving U.S. Food and Drug Administration (FDA) Investigational Device Exemption ...

Home July 01, 2020
Home
News | Cardiovascular Clinical Studies

January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special ...

Home January 20, 2020
Home
News | Cardiovascular Clinical Studies

Environmental and lifestyle issues were popular this year, with pick up from both European Society of Cardiology (ESC) ...

Home December 23, 2019
Home
News | Cardiovascular Clinical Studies

November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have ...

Home November 26, 2019
Home
News | Cardiovascular Clinical Studies

July 10, 2019 — The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During ...

Home July 10, 2019
Home
News | Cardiovascular Clinical Studies

July 3, 2019 — The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to ...

Home July 03, 2019
Home
News | Cardiovascular Clinical Studies

November 19, 2018 — The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent ...

Home November 19, 2018
Home
Subscribe Now